Search

Search Results

7 results for “A. Doretti”

Sort by

OC18 | LONG-TERM EFFECTIVENESS, SAFETY AND TOLERABILITY OF ATOGEPANT IN THE PREVENTION OF MIGRAINE: A MULTICENTRIC, PROSPECTIVE OBSERVATIONAL, REAL WORLD STUDY (THE 48-WEEK STAR STUDY)

F. Vernieri^1|2, L. Francesco Iannone³, M. Marcosano^1|2, L. Fofi¹, F. Lo Castro⁴, G. Sebastianelli⁵, F. De Santis⁶, M. Corrado⁷, R. Ornello⁶, L. Grazzi⁸, D. Antonio Montisano⁸, F. De Cesaris⁹, A. Munafò⁹, G. Avino¹⁰, M. Trimboli¹¹, M. Albanese¹², A. Russo¹³, M. Silvestro¹³, G. Dalla Volta¹⁴, M. Romozzi¹⁵, P. Calabresi¹⁵, A. Boccalini⁴, P. Merlo¹⁶, M. Pia Prudenzano¹⁷, M. Rosaria Valente¹⁸, I. Rainero¹⁹, G. Giuliani²⁰, M. Altieri²⁰, A. Doretti²¹, G. Vaghi^7|22, F. Pistoia⁶, D. Ferrandi²³, S. Battistini²⁴, G. Coppola⁵, S. Guerzoni⁴, S. Sacco^6|25, C. Tassorelli^7|22, C. Altamura^1|2 | ¹Headache and Neurosonology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; ²Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; ³Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy; ⁴Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico Di Modena, Italy; ⁵Sapienza University of Rome, Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino, Latina, Italy; ⁶Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; ⁷Headache Science and Neurorehabilitation Centre, IRCCS Mondino Foundation, Pavia, Italy; ⁸Headache Center IRCCS Fondazione Istituto Neurologico "Carlo Besta", Italy; ⁹Headache center and clinical pharmacology, AOU Careggi, Firenze, Italy; ¹⁰Neurology Unit, Ospedale Santo Stefano, USL Toscana Centro, Prato, Italy; ¹¹Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro, Italy; ¹²Department of Systems Medicine, University of Rome Tor Vergata, Italy; ¹³Headache Center, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Italy; ¹⁴U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Italy; ¹⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; ¹⁶UO di Neurologia, Humanitas Gavazzeni, Bergamo, Italy; ¹⁷Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Italy; ¹⁸Clinica Neurologica ASUFC, Dipartimento di Medicina DMED Università di Udine, Italy; ¹⁹Headache Center, Department of Neuroscience, University of Torino, Italy; ²⁰Department of Human Neuroscience, Sapienza University of Rome, Italy; ²¹IRCCS Istituto Auxologico Italiano, Milano, Italy; ²²Department of Brain and Behavioural Sciences, University of Pavia, Italy; ²³SC Neurologia, Azienda Ospedaliero Universitaria Santi Antonio e Biagio, Alessandria, Italy; ²⁴Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy; ²⁵Neurology and Stroke Unit, ASL 1 Abruzzo, Avezzano-Sulmona-L’Aquila, Italy

03-11-2026

DOI https://doi.org/10.4081/cc.2026.15956
- 0 abstract views
- 0 PDF
P103 | ALEXITHYMIA INCREASES THE RISK OF MIGRAINE CHRONIFICATION IN WOMEN WITHOUT DEPRESSION

E. Rota¹, E. Rubino², V. Batti², M. Trucco¹, S. Bottiroli^3|4, M. Cangelosi^3|4, A. Doretti⁵, F. Govone⁶, D. Ferrandi⁷, C. Lanni⁷, C. Cavestro⁸, M. Demaestri⁸, E. Canale⁹, V. Sciruicchio¹⁰, A. Di Gioia¹⁰, A. Passarini¹¹, I. Toldo¹², S. Di Antonio¹, A. Versace¹³, E. Cavagnetto¹, L. Savi², A. Battaggia¹⁴ | ¹Neurology Unit, San Giacomo Hospital, Novi Ligure, ASL AL, Italy; ²Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Italy; ³Department of Brain and Behavioral Sciences, University of Pavia, Italy; ⁴IRCCS Mondino Foundation, Pavia, Italy; ⁵Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy; ⁶Neurology Unit, Regina Montis Regalis Hospital, Mondovì, ASL CN1, Italy; ⁷Neurology Unit, San Biagio e Arrigo Hospital, Alessandria, AOU AL, Italy; ⁸Headache Center, Alba, ASL CN2, Italy; ⁹Child Neuropsychiatry Unit, IRCCS Istituto G. Gaslini, Genoa, Italy; ¹⁰Children Epilepsy and EEG Center, Bari, Italy; ¹¹Child Neuropsychiatry Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; ¹²Unit of Child Neurology and Neurophysiology, Women’s and Children’s Health Department University of Padova, Italy; ¹³Pediatric Headache Centre, Department of Pediatric Emergency, Regina Margherita Children’s Hospital, Turin, Italy; ¹⁴SVEMG – Scuola Veneta di Medicina Generale, Padova, Italy

03-11-2026

DOI https://doi.org/10.4081/cc.2026.16059
- 0 abstract views
- 0 PDF
P047 | ONABOTULINUMTOXIN-A EFFECTIVENESS EVALUATION IN CHRONIC MIGRAINE PATIENTS WITH SHORT OR LONG DISEASE HISTORY AND PSYCHIATRIC COMORBIDITIES: AN ITALIAN MULTICENTRIC STUDY (THE BACH STUDY)

F. Vernieri^1|2, P. Pasqualetti³, M. Marcosano^1|2, N. Brunelli⁴, L. Fofi¹, D. Antonio Montisano⁵, L. Grazzi⁵, R. Ornello⁶, C. Rosignoli⁶, A. Doretti⁷, E. Colombo⁷, M. Albanese⁸, G. Viticchi⁹, S. Migliore⁶, S. Sacco⁶, C. Altamura^1|2 | ¹Headache and Neurosonology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; ²Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; ³Section of Health Statistics and Biometry, Department WHES (Wellbeing, Health & Environmental Sustainability), Sapienza University of Rome, Italy; ⁴Department of Neurology, Vall d’Hebron Research Institute, Barcelona, Spain; ⁵Headache Center, IRCCS Fondazione Istituto Neurologico "Carlo Besta", Milano, Italy; ⁶Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; ⁷Department of Systems Medicine, University of Rome Tor Vergata, Italy; ⁸IRCCS Istituto Auxologico Italiano, Milano, Italy; ⁹Neurological Clinic, Experimental and Clinical Medicine Department, Marche Polytechnic University, Ancona, Italy

03-11-2026

DOI https://doi.org/10.4081/cc.2026.16003
- 0 abstract views
- 0 PDF
P032 | IMPROVEMENT IN DEPRESSIVE AND ANXIETY SYMPTOMS DURING EPTINEZUMAB TREATMENT: A POST-HOC ANALYSIS FROM THE TACHIS STUDY

E.M. Piella¹, A.M. Chiarandon¹, V. Batti¹, D.A. Montisano², L. F. Iannone³, C. Fasano⁴, G. Sebastianelli⁵, G. Coppola⁵, D. Ferrandi⁶, C. Lanni⁷, M.P. Prudenzano⁸, M. De Tommaso⁹, P. Merlo¹⁰, A. Viganò¹⁰, F. De Cesaris¹¹, A. Chiarugi¹¹, A. Munafò¹¹, F. Pistoia¹², R. Ornello¹², S. Sacco¹², A. Doretti¹³, L. Grazzi², F. Lo Castro¹⁴, R. Allamprese¹⁴, R. De Icco^15|16, G. Vaghi^15|16, C. Tassorelli^15|16, G. Avino¹⁷, M. Romozzi¹⁸, C. Vollono¹⁸, P. Calabresi¹⁸, S. Battistini¹⁹, A. Rufa¹⁹, M. Albanese²⁰, M. Trimboli²¹, G. Carlucci⁴, M. Silvestro²², A. Russo²², M. Valente²³, L. Fofi²⁴, M. Marcosano²⁴, P. Geppetti²⁵, C. Altamura²⁴, F. Vernieri²⁴, E. Rubino¹, I. Rainero¹, S. Guerzoni¹⁴ | ¹Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Italy; ²Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy; ³Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy; ⁴NEUROFARBA Department, University of Florence - Neurologia, AOU Careggi, Italy; ⁵Sapienza University of Rome, Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino, Latina, Italy; ⁶AOU Alessandria, SC Neurologia, Italy; ⁷Psicologia AOU Alessandria, Italy; ⁸Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Consorziale di Bari, Italy; ⁹Neurophysiopathology Unit, Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Italy; ¹⁰UO di Neurologia, Humanitas Gavazzeni, Bergamo, Italy; ¹¹Headache center and Clinical pharmacology unit, AOU Careggi, Florence, Italy; ¹²Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy; ¹³Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy; ¹⁴Digital and Predictive Medicine, Pharmacology, Clinical Metabolic Toxicology-Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico, Modena, Italy; ¹⁵Department of Brain and Behavioral Sciences, University of Pavia, Italy; ¹⁶Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy; ¹⁷SOC Neurologia, Ospedale di Prato, Italy; ¹⁸Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; ¹⁹Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy; ²⁰Unit of Neurology, Department of Systems Medicine, University of Rome Tor Vergata, Italy; ²¹Headache Center, Unit of Neurology, AOU Renato Dulbecco, Catanzaro, Italy; ²²Inter-departmental Program of Headache Medicine and Primary Pain Syndromes, Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy; ²³DMED, University of Udine and Clinical Neurology, Udine University Hospital, Italy; ²⁴Fondazione Policlinico Universitario Campus Bio-Medico, Roma e Università Campus Bio-Medico di Roma, Italy; ²⁵Department of Molecular Pathobiology and Pain Research Center, College of Dentistry, New York University, NY, USA

03-11-2026

DOI https://doi.org/10.4081/cc.2026.15988
- 0 abstract views
- 0 PDF
P093 | GAINER-AI: PREDICTING ACUTE RIMEGEPANT RESPONSE IN MIGRAINE USING MACHINE LEARNING IN A MULTICENTER REAL-WORLD COHORT

M. Romozzi^1|2, A. Lokhawandala³, G. Vaghi^4|5, G. Sebastianelli⁶, R. Ornello⁷, F. Casillo⁶, A. Russo⁸, M. Silvestro⁸, F. Pistoia⁹, G. Saporito⁹, G. Dalla Volta¹⁰, M. Bolchini¹⁰, A. Burgalassi¹¹, G. Vigani¹¹, D. Antonio Montisano¹², L. Grazzi¹², M. Pia Prudenzano¹³, D. Mascarella¹⁴, E. Mampreso¹⁵, G. Avino¹⁶, M. Valente¹⁷, G. Carlucci¹⁸, S. Guerzoni¹⁹, S. Battistini²⁰, A. Granato²¹, E. Maria Piella²², I. Rainero²², M. Albanese²³, M. Trimboli²⁴, A. Doretti²⁵, F. De Santis⁷, S. Sacco⁷, C. Tassorelli^4|5, S. Di Tella²⁶, C. Vollono^1|2, P. Calabresi^1|2, R. De Icco^4|5, L. Francesco Iannone²⁷ | ¹Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; ²Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; ³Drexel University, Philadelphia, USA; ⁴Department of Brain and Behavioral Sciences, University of Pavia, Italy; ⁵Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy; ⁶Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina, Italy; ⁷Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; ⁸Headache Centre, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy; ⁹Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy; ¹⁰Headache Center of Clinical Neurology of Istituto Clinico Città Di Brescia, Italy; ¹¹Department of Health Sciences, University of Florence, Italy; ¹²Neuroalgology Unit and Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; ¹³Headache Center, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Italy; ¹⁴IRCCS Istituto Di Scienze Neurologiche Di Bologna, Programma Cefalee e Algie Facciali, Italy; ¹⁵Headache Centre, Neurology - Euganea, Health Unit, Padua, Italy; ¹⁶Neurology Unit, Ospedale Santo Stefano, USL Toscana Centro, Prato, Italy; ¹⁷Clinical Neurology, Azienda Sanitaria Universitaria Friuli Centrale, Presidio Ospedaliero Santa Maria Della Misericordia, Udine, Italy; ¹⁸NEUROFARBA Department, University of Florence - AOU Careggi, Italy; ¹⁹Digital and Predictive Medicine, Pharmacology, Clinical Metabolic Toxicology-Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico, Modena, Italy; ²⁰Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy; ²¹Headache Centre, Clinical Unit of Neurology, School of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste, ASUGI, University of Trieste, Italy; ²²Department of Neurosciences “Rita Levi Montalcini”, University of Turin, Italy; ²³Unit of Neurology, Department of Systems Medicine, Tor Vergata University, Rome, Italy; Unit of Neurology - IRCCS Neuromed, Pozzilli (IS), Italy; ²⁴Headache Centre, Neurology Unit, AOU Renato Dulbecco, Catanzaro, Italy; ²⁵Department of Neurology- Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy; ²⁶Dipartimento di Psicologia, Università Cattolica del Sacro Cuore, Milan, Italy; ²⁷Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy

03-11-2026

DOI https://doi.org/10.4081/cc.2026.16049
- 0 abstract views
- 0 PDF
P053 | LONG-TERM EFFECTIVENESS AND SAFETY OF FREMANEZUMAB FOR MIGRAINE PREVENTION: 24-MONTH OUTCOMES FROM THE ITALIAN COHORT OF THE PEARL STUDY

S. Guerzoni¹, C. Aurilia², A. Doretti³, E. Maria Piella⁴, R. Ornello⁵, P. Kokturk⁶, M. Cepparulo⁷ | ¹Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology- Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Italy; ²Headache and Pain Unit, IRCCS San Raffaele, Rome, Italy; ³Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; ⁴Neurosciences Department, University of Turin, Italy; ⁵Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; ⁶Teva Netherlands B.V., Haarlem, The Netherlands; ⁷Teva Italia Srl, Milan, Italy

03-11-2026

DOI https://doi.org/10.4081/cc.2026.16009
- 0 abstract views
- 0 PDF
P025 | PAIN RELIEF AFTER 30 MINUTES PREDICTS COMPLETE ACUTE TREATMENT SUCCESS AT 12 HOURS: A REAL-WORLD ANALYSIS OF INTRAVENOUS EPTINEZUMAB INFUSION IN HIGHLY REFRACTORY MIGRAINE PATIENTS

L. Fofi¹, C. Altamura^1|2, M. Marcosano^1|2, L. d’Onofrio², A. Doretti³, F. Pistoia⁴, A. Granato⁵, S. Guerzoni⁶, M. Trimboli⁷, L. Grazzi⁸, D. Antonio Montisano⁸, G. Avino⁹, G. Sebastianelli¹⁰, C. Fasano¹¹, E. Maria Piella¹², P. Geppetti¹³, N. Brunelli¹, S. Lodico², L. Francesco Iannone¹⁴, F. Vernieri^1|2 | ¹Neurosonology and Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; ²Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Italy; ³Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; ⁴Department of Biotechnological and Applied Clinical Sciences, Neurological Institute, University of L’Aquila, Italy; ⁵Headache Center, Neurology Clinic, University Hospital of Trieste, University of Trieste, Italy; ⁶Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinico di Modena, Italy; ⁷Azienda Ospedaliera-Universitaria “Renato Dulbecco”, Catanzaro, Italy; ⁸Headache Center, Department of Neurology, IRCCS Foundation “Carlo Besta” Neurological Institute, Milan, Italy; ⁹SOC Neurologia, Ospedale Santo Stefano, USL Toscana Centro, Prato, Italy; ¹⁰Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino ICOT, Sapienza University of Rome, Latina, Italy; ¹¹Headache and Cerebrovascular Diseases Center, Neurology Unit 2, Careggi University Hospital, Florence, Italy; ¹²Department of Neurosciences “Rita Levi Montalcini”, University of Turin, Italy; ¹³Department of Molecular Pathobiology and Pain Research Center, College of Dentistry, New York University, NY, United States; ¹⁴Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy

03-11-2026

DOI https://doi.org/10.4081/cc.2026.15981
- 0 abstract views
- 0 PDF

1 - 7 of 7 items

Search

Search Results

OC18 | LONG-TERM EFFECTIVENESS, SAFETY AND TOLERABILITY OF ATOGEPANT IN THE PREVENTION OF MIGRAINE: A MULTICENTRIC, PROSPECTIVE OBSERVATIONAL, REAL WORLD STUDY (THE 48-WEEK STAR STUDY)

P103 | ALEXITHYMIA INCREASES THE RISK OF MIGRAINE CHRONIFICATION IN WOMEN WITHOUT DEPRESSION

P047 | ONABOTULINUMTOXIN-A EFFECTIVENESS EVALUATION IN CHRONIC MIGRAINE PATIENTS WITH SHORT OR LONG DISEASE HISTORY AND PSYCHIATRIC COMORBIDITIES: AN ITALIAN MULTICENTRIC STUDY (THE BACH STUDY)

P032 | IMPROVEMENT IN DEPRESSIVE AND ANXIETY SYMPTOMS DURING EPTINEZUMAB TREATMENT: A POST-HOC ANALYSIS FROM THE TACHIS STUDY

P093 | GAINER-AI: PREDICTING ACUTE RIMEGEPANT RESPONSE IN MIGRAINE USING MACHINE LEARNING IN A MULTICENTER REAL-WORLD COHORT

P053 | LONG-TERM EFFECTIVENESS AND SAFETY OF FREMANEZUMAB FOR MIGRAINE PREVENTION: 24-MONTH OUTCOMES FROM THE ITALIAN COHORT OF THE PEARL STUDY

P025 | PAIN RELIEF AFTER 30 MINUTES PREDICTS COMPLETE ACUTE TREATMENT SUCCESS AT 12 HOURS: A REAL-WORLD ANALYSIS OF INTRAVENOUS EPTINEZUMAB INFUSION IN HIGHLY REFRACTORY MIGRAINE PATIENTS